Clinical Trials Logo

Filter by:
NCT ID: NCT06454032 Completed - Postmenopause Women Clinical Trials

Effect of 12-week FW Programme on Sex Hormone Levels and Risk Factors for MS in Postmenopausal Women

Start date: April 16, 2022
Phase: N/A
Study type: Interventional

Postmenopausal women were separated into two groups: one participating in a 12-week fitness walking programe as the fitness walking group, and the other maintaining their regular lifestyle as the control group. The study evaluated alterations in health markers and examined the correlation between metabolic syndrome risk factors and sex hormone levels before and after the intervention.

NCT ID: NCT06453902 Not yet recruiting - Clinical trials for Chronic Myeloid Leukemia

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Start date: June 15, 2024
Phase: Phase 2
Study type: Interventional

A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment

NCT ID: NCT06453889 Not yet recruiting - Lung Cancer Clinical Trials

Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer

Start date: June 5, 2024
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of multimode thermal therapy for early peripheral lung cancer, and to explore the changes of systemic immune microenvironment after multimode thermal therapy.

NCT ID: NCT06453395 Completed - Clinical trials for Tumor Regression Grade

PPIO-009 Tumor Regression Grade and Tumor Location in Esophageal Cancer

Start date: January 1, 2023
Phase:
Study type: Observational

At present, the evaluation of the effect of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal cancer is mainly based on postoperative pathology, among which, the pathological assessment of tumor regression grade (TRG) and TNM staging are the basis for the routine pathological diagnosis of esophageal cancer, and the College of American Pathologists divides the TRG after neoadjuvant therapy to esophageal cancer into four grades: 0, 1, 2, and 3.The residual primary tumor in the resection specimen following neoadjuvant therapy is associated with shorter overall survival. Therefore ,the prediction of TRG after neoadjuvant therapy is vital for patients. We aim to seek to identify factors associated with TRG system as defined by the NCCN.

NCT ID: NCT06453135 Not yet recruiting - Clinical trials for Kidney Transplantation

Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation

Start date: July 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to determine whether a single dose of eculizumab can effectively prevent antibody-mediated rejection in recipients undergoing living donor kidney transplantation with a different ABO blood group type than their donors

NCT ID: NCT06453057 Recruiting - Adult Clinical Trials

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

Start date: June 6, 2024
Phase: N/A
Study type: Interventional

This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT307) for treatment of patients with solid tumours,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).

NCT ID: NCT06452953 Completed - Clinical trials for Chronic Insomnia Disorder

Modified Suanzaoren Decoction Versus Eszopiclone for the Treatment of Chronic Insomnia Disorder

Start date: September 10, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to observe the cognitive function and clinical efficacy of modified Suanzaoren decoction and eszopiclone in the treatment of chronic insomnia disorder patients, and to investigate the possible neural mechanisms using MRI techniques.

NCT ID: NCT06452862 Recruiting - Clinical trials for Diabetic Kidney Disease

Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease

Start date: May 5, 2024
Phase:
Study type: Observational

The goal of this study is to investigate the value of noninvasive evaluation of multimodal magnetic resonance imaging in diagnosis and treatment of diabetic kidney disease (DKD). We aim to explore the feasibility of multimodal magnetic resonance imaging in the staging diagnosis of DKD, and establish a non-invasive method for evaluating the progression of DKD disease by combining imaging and biochemical indicators. Multimodal magnetic resonance examinations will be performed on diabetic patients with different stages as well as regular follow-up during treatment, in order to investigate the relationship between imaging findings and pathophysiological changes of the kidneys.

NCT ID: NCT06452849 Recruiting - Clinical trials for Major Depressive Disorder

Amygdala and dLPFC MRI-TIS for Depression in Adolescents

Start date: May 27, 2024
Phase: N/A
Study type: Interventional

The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in adolescent depressive disorders.

NCT ID: NCT06452823 Enrolling by invitation - Hypothyroidism Clinical Trials

Efficacy and Safety of Catheter Ablation of Atrial Fibrillation in Patients With Thyroid Hormone Stabilization

SQUIRREL
Start date: May 1, 2024
Phase:
Study type: Observational

Patients with hyperthyroidism or hypothyroidism are often combined with atrial fibrillation, but after the stabilization of thyroid hormone levels after treatment, the patients' atrial fibrillation still persists. Radiofrequency ablation of the atrial fibrillation as one of the treatment options for atrial fibrillation has been widely used in the clinic, and has significant efficacy in maintaining sinus rhythm, improving cardiac function, and improving the prognosis of patients. However, there is a lack of clinical monitoring data on radiofrequency ablation of atrial fibrillation in patients who have combined thyroid dysfunction and have stabilized their thyroid hormone levels after treatment.